3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
8
Phase 3
4
Phase NA
3
Phase 4
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
112
Breast Neoplasms
79
Neoplasms
74
Neoplasm Metastasis
63
Colorectal Neoplasms
62
Prostatic Neoplasms
57
Recurrence
56
Pancreatic Neoplasms
54
Leukemia, Myeloid, Acute
54
Ovarian Neoplasms
53
Multiple Myeloma
50
Melanoma
39
Glioblastoma
38
Squamous Cell Carcinoma of Head and Neck
33
Lung Neoplasms
33
Triple Negative Breast Neoplasms
31
Lymphoma, Non-Hodgkin
30
Endometrial Neoplasms
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Lymphoma
27
Carcinoma, Renal Cell
27
Lymphoma, Large B-Cell, Diffuse
26
Stomach Neoplasms
25
Lymphoma, B-Cell
25
Carcinoma, Hepatocellular
24
Advanced Solid Tumor
24
Small Cell Lung Carcinoma
23
Leukemia, Lymphocytic, Chronic, B-Cell
23
Burkitt Lymphoma
23
Brain Neoplasms
23
Interventions
pembrolizumab
1
enfortumab vedotin
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Urologic Neoplasms
×
90 days
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA